BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
Adding mitomycin to bladder cancer treatment did not improve survival compared to bacillus calmette-guerin alone in this trial
This randomized Phase 3 trial enrolled 501 BCG-naive patients with high-grade pTa or any grade pT1 non-muscle-invasive bladder cancer. The s…
Doctors tested adding mitomycin to standard bladder cancer therapy. Patients receiving both drugs did not live longer without disease than t…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer
Bladder Preservation May Be Safe for Older Bladder Cancer Patients
This meta-analysis of 4888 elderly patients with muscle-invasive bladder cancer found no significant difference in 1-, 5-, and 10-year overa…
For older adults with aggressive bladder cancer, keeping the bladder may offer survival rates equal to surgery for the first five years, but…
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
Case report and literature review on mosaic DICER1 mutations and disease stability in a 6-month-old boy
One Baby, Five Tumors, One Tiny Gene Change
This case report and literature review describes a 6-month-old boy with mosaic DICER1 RNase IIIb hotspot mutation and multiple tumors.
A 6-month-old boy developed five different tumors linked to one small gene change, showing how one mutation can drive multiple childhood can…
Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
Old cancer drugs failed, but one new drug saves high-risk kidney patients today
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
Open-source CT scans aim to boost kidney cancer AI research
This cohort study involved 101 patients with renal cell carcinoma (RCC) and analyzed 142 annotated CT scans.
Researchers release 142 annotated CT scans from 101 kidney cancer patients to accelerate AI development.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.